Summit Therapeutics
SMMT
9.95
-0.62
-5.87%
Summit Therapeutics
US · SMMT
#1207 by market cap
Listed 2015
9.95
-0.62
-5.87%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
Quant vs Street three independent views, side by side
StockVane factor grade
D+
Momentum strategy signal
Strong Sell
Analyst consensus
Buy
Mostly aligned, one view stands apart.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
✦ Quant Analyst Revision Trend how this is computed
Improving
3 1
■ Upgrades■ Downgrades
- 3 upgrades vs 1 downgrade among tracked analyst rating changes.
- Most recent: Leerink Partners moved from Sell to Hold on 2026-11-18.
Analyst consensus 13 analysts
Buy
Avg price target 27.57 +177.1%
Price target rangecurrent 9.95
Low8.30
Avg27.57
High43.00
Buy 62%
Hold 31%
Sell 8%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-11-19 | Leerink Partners | -- | Hold | 11.00 |
| 2026-11-18 | Bernstein | -- | Sell | 8.30 |
| 2026-11-18 | Leerink Partners | -- | Hold | -- |
| 2026-11-17 | H.C. Wainwright | -- | Hold | -- |
| 2026-11-16 | Piper Sandler | -- | Hold | 16.00 |
| 2026-11-16 | Stifel | -- | Buy | 37.00 |
| 2026-11-16 | Citi | -- | Buy | 42.00 |
| 2026-11-16 | H.C. Wainwright | -- | Hold | -- |
| 2026-11-16 | Barclays | -- | Hold | 18.00 |
| 2026-11-15 | Wells Fargo | -- | Buy | 30.00 |
| 2026-11-15 | Citi | -- | Buy | 42.00 |
| 2026-11-15 | Goldman Sachs | -- | Buy | 43.00 |
| 2026-11-11 | Wells Fargo | -- | Buy | 30.00 |
| 2026-11-05 | Evercore | -- | Buy | 34.00 |
| 2026-11-05 | Stifel | -- | Buy | 37.00 |
| 2026-11-05 | Citi | -- | Buy | 43.00 |
| 2026-11-05 | H.C. Wainwright | -- | Hold | -- |
| 2026-11-04 | Goldman Sachs | -- | Buy | 43.00 |
| 2026-11-04 | Barclays | -- | Hold | 20.00 |
| 2026-11-02 | H.C. Wainwright | -- | Hold | -- |
| 2026-10-27 | H.C. Wainwright | -- | Hold | -- |
| 2026-10-26 | UBS | -- | Buy | 33.00 |
| 2026-10-26 | Citi | -- | Buy | 43.00 |
| 2026-10-25 | Goldman Sachs | -- | Buy | 43.00 |
| 2026-10-23 | H.C. Wainwright | -- | Hold | -- |
Price target trend monthly average, last 3 years
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-11-18 | Leerink Partners | Sell → Hold | -- |
| 2026-09-09 | Jefferies | Hold → Buy | 25.00 |
| 2026-05-22 | H.C. Wainwright | Buy → Hold | -- |
| 2025-12-17 | Barclays | Sell → Hold | 18.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q3 | 2026-11-04 | After close | ±8.99% | -12.24% (beat) |
| 2026/Q2 | 2026-07-23 | After close | ±16.02% | -8.81% (in line) |
| 2025/Q4 | 2026-02-23 | After close | ±9.35% | +0.19% (in line) |
| 2025/Q3 | 2025-10-20 | -- | ±21.61% | -4.55% (in line) |
| 2025/Q1 | 2025-05-01 | After close | ±12.42% | +13.09% (beat) |
| 2024/Q4 | 2025-02-24 | -- | ±14.52% | -14.83% (beat) |
| 2024/Q3 | 2024-10-30 | -- | ±9.81% | -14.57% (beat) |
| 2024/Q2 | 2024-08-06 | -- | ±15.76% | -4.74% (in line) |
| 2024/Q1 | 2024-05-01 | -- | ±26.01% | +19.59% (in line) |
| 2023/Q4 | 2024-02-20 | -- | ±22.19% | -26.23% (beat) |
| 2023/Q3 | 2023-11-07 | -- | ±31.74% | -12.16% (in line) |
| 2023/Q2 | 2023-08-09 | -- | ±19.66% | +10.86% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-11-20 20:02:25 · For reference only, not investment advice and not tailored to your situation.
Summit Therapeutics discussion 0 comments